A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Inclusion Criteria:

• Diagnosis of:

-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed fromfollicular lymphoma (FL) or nodal marginal zone lymphoma) with histologicallyconfirmed CD20+ disease, inclusive of the following according to World HealthOrganization (WHO) 2016 classification and documented in pathology report:

• DLBCL, not otherwise specified (NOS).

• High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations perWHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOSor other double- /triple-hit lymphomas (with histologies not consistent withDLBCL) are not eligible.

• Follicular lymphoma (FL) Grade 3B. OR

• FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologictransformation to an aggressive lymphoma at most recent representative tumor biopsy,according to WHO 2016 classification. OR

• Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at mostrecent representative tumor biopsy according to the WHO 2016 classification withevidence of overexpression of cyclin D1 in association with relevant markers orevidence of t(11;14) assessed by flow cytometry, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR).

• Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arms 6, 7, and 8 where ECOG performance status must be 0-1.

• Must have 1 or more measurable disease sites:

• A positron emission tomography (PET) /computed tomography (CT) scandemonstrating PET-positive lesion(s) AND

• At least 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurableextra-nodal lesion (long axis > 1.0 cm) on CT scan or magnetic resonanceimaging (MRI).

Exclusion Criteria:

• Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 andCD20.

• Toxicities from prior anticancer therapy that have not resolved to CommonTerminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with theexception of alopecia. Other eligibility criteria (e.g., laboratory, cardiaccriteria) must also be met.